- Home
- XXII vs PMCB Comparison
XXII vs PMCB Comparison
Compare XXII & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XXII
- PMCB
- Stock Information
- Founded
- XXII 1998
- PMCB 1996
- Country
- XXII United States
- PMCB United States
- Employees
- XXII N/A
- PMCB N/A
- Industry
- XXII Medicinal Chemicals and Botanical Products
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- XXII Health Care
- PMCB Health Care
- Exchange
- XXII Nasdaq
- PMCB Nasdaq
- Market Cap
- XXII 7.0M
- PMCB 7.3M
- IPO Year
- XXII N/A
- PMCB N/A
- Fundamental
- Price
- XXII $5.95
- PMCB $1.11
- Analyst Decision
- XXII
- PMCB
- Analyst Count
- XXII 0
- PMCB 0
- Target Price
- XXII N/A
- PMCB N/A
- AVG Volume (30 Days)
- XXII 54.0K
- PMCB 12.7K
- Earning Date
- XXII 08-12-2025
- PMCB 08-12-2025
- Dividend Yield
- XXII N/A
- PMCB N/A
- EPS Growth
- XXII N/A
- PMCB N/A
- EPS
- XXII N/A
- PMCB 1.29
- Revenue
- XXII $23,869,000.00
- PMCB N/A
- Revenue This Year
- XXII $22.41
- PMCB N/A
- Revenue Next Year
- XXII $76.35
- PMCB N/A
- P/E Ratio
- XXII N/A
- PMCB $0.85
- Revenue Growth
- XXII N/A
- PMCB N/A
- 52 Week Low
- XXII $5.73
- PMCB $1.00
- 52 Week High
- XXII $2,837.04
- PMCB $2.42
- Technical
- Relative Strength Index (RSI)
- XXII 19.09
- PMCB 51.40
- Support Level
- XXII $5.73
- PMCB $1.06
- Resistance Level
- XXII $9.50
- PMCB $1.15
- Average True Range (ATR)
- XXII 1.33
- PMCB 0.05
- MACD
- XXII 0.13
- PMCB 0.01
- Stochastic Oscillator
- XXII 3.43
- PMCB 60.00
About XXII 22nd Century Group Inc.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.